BC
PTGX icon

Bridgefront Capital’s Protagonist Therapeutics PTGX Stock Holding History

Bridgefront Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,545
Closed -$251K – 782
2025
Q2 		$251K Buy
+4,545
New +$218K 0.07% 488
2024
Q1 		– Sell
-11,370
Closed -$261K – 525
2023
Q4 		$261K Buy
+11,370
New +$199K 0.2% 207
2022
Q4 		– Sell
-12,084
Closed -$102K – 487
2022
Q3 		$102K Buy
+12,084
New +$114K 0.1% 276

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bridgefront Capital's PTGX Position: Q3 2025 in Review

Bridgefront Capital sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 4,545 shares — an estimated $251K sold.

Bridgefront Capital first reported a position in PTGX in Q3 2022 and held it in 3 quarters. The position peaked at $261K in Q4 2023. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Bridgefront Capital reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bridgefront Capital sold 4,545 Protagonist Therapeutics shares in Q3 2025, an estimated $251K.
  • Bridgefront Capital first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 3 quarters.
  • Bridgefront Capital's Protagonist Therapeutics position peaked at $261K in Q4 2023.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.